Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $41
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $38 to $41.
Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $38 to $41.